NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases, 1 stable over time, 2 and, if present in blood at allele fractions ≥0.01% ...

Emilie Aschenbrenner, PharmD, BCOP, highlights how measurable residual disease (MRD) testing can support value-based care in ...

MRD testing is crucial for high-risk MM patients, aiding in early detection and treatment decisions, despite logistical and insurance barriers. Physicians primarily use MRD to monitor remission ...

The findings show that molecular MRD after induction chemotherapy can identify patients with NPM1 -mutated AML who are more likely to benefit from transplant in first remission, Othman concluded.

Minimal residual disease (MRD) testing is becoming a cornerstone of oncology by enabling early detection of cancer recurrence and guiding timely adjustments to therapy from a blood sample.

QIAGEN (NYSE:QGEN) said on Monday that it has expanded its oncology diagnostics portfolio with two partnerships to advance the use of minimal residual disease testing in clinical trials. The ...

Impact of pre-transplant MRD on AML prognosisMeasurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia Pranay S. Hegde Georgia Andrew ...